---
title: Phase 1 study combining elotuzumab with autologous stem cell transplant and
  lenalidomide for multiple myeloma
date: '2024-04-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38609316/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=12guA9dSu1tIGuMz6q_NmVi5YCwW3jEzF9ajGRxJKG5GGImktL&fc=20220328030059&ff=20240413180315&v=2.18.0.post9+e462414
source: (stem cell transplantation) AND (immune reconstitution) AND (tumor microenvironment)
description: 'CONCLUSIONS: This phase 1 clinical trial demonstrates that early introduction
  of immunotherapy after ASCT is well tolerated and shows promising disease control
  in patients with MM, accompanied by favorable changes in the immune ...'
disable_comments: true
---
CONCLUSIONS: This phase 1 clinical trial demonstrates that early introduction of immunotherapy after ASCT is well tolerated and shows promising disease control in patients with MM, accompanied by favorable changes in the immune ...